‘Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies,Galveston,TX,USA,April 2010
Restricted accessResearch articleFirst published online February, 2011
‘Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies,Galveston,TX,USA,April 2010
Abstract: Current classification criteria for definite APS recommend the use of one or more of three positive standardized laboratory assays, including anticardiolipin antibodies (aCL), lupus anticoagulant (LA), and antibodies directed to β2glycoprotein I (anti-β2GPI) to detect antiphospholipid antibodies (aPL) in the presence of at least one of the two major clinical manifestations (i.e., thrombosis or pregnancy morbidity) of the syndrome. Several other autoantibodies shown to be directed to phospholipids and/or their complexes with phospholipids and/or to proteins of the coagulation cascade, as well as a mechanistic test for resistance to annexin A5 anticoagulant activity, have been proposed to be relevant to APS. A task force of worldwide scientists in the field discussed and analyzed critical questions related to ‘non-criteria’ aPL tests in an evidence-based manner during the 13th International Congress on Antiphospholipid Antibodies (APLA 2010, 13–16 April 2010, Galveston, Texas, USA). This report summarizes the findings, conclusions, and recommendations of this task force.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
2.
BertolacciniMLHughesGRKhamashtaMA. Revisiting antiphospholipid antibodies: from targeting phospholipids to phospholipid binding proteins. Clin Lab2004; 50: 653–665.
3.
GrisJCQuereISanmarcoM. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstetricians and Haematologists Study – NOHA. Thromb Haemost2000; 84: 228–236.
4.
SugiTMatsubayashiHInomoADanLMakinoT. Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss. J Obstet Gynaecol Res2004; 30: 326–332.
5.
SanmarcoMGayetSAlessiMC. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost2007; 97: 949–954.
6.
SanmarcoM. ELISA for antiphosphatidylethanolamine antibody detection: high impact of assay buffer on results. J Immunol Methods2010; 358: 9–16.
7.
de LaatBMertensKde GrootPG. Mechanisms of disease: antiphospholipid antibodies – from clinical association to pathologic mechanism. Nat Clin Pract Rheumatol2008; 4: 192–199.
8.
de LaatBDerksenRHvan LummelMPenningsMTde GrootPG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood2006; 107: 1916–1924.
9.
IversonGMVictoriaEJMarquisDM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A1998; 95: 15542–15546.
10.
IversonGMReddelSVictoriaEJ. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol2002; 169: 7097–7103.
11.
IoannouYPericleousCGilesILatchmanDSIsenbergDARahmanA. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum2007; 56: 280–290.
12.
de LaatBDerksenRHUrbanusRTde GrootPG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood2005; 105: 1540–1545.
13.
de LaatBPengoVPabingerI. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost2009; 7: 1767–1773.
14.
IoannouYRomay-PenabadZPericleousC. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost2009; 7: 833–842.
15.
PetriM. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res2004; 114: 593–595.
16.
FinazziGBrancaccioVMoiaM. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med1996; 100: 530–536.
17.
Abu-ShakraMGladmanDDUrowitzMBFarewellV. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med1995; 99: 624–628.
18.
AhmedEStegmayrBTrifunovicJWeinehallLHallmansGLefvertAK. Anticardiolipin antibodies are not an independent risk factor for stroke: An incident case-referent study nested within the MONICA and Vasterbotten cohort project. Stroke2000; 31: 1289–1293.
19.
BreyRLAbbottRDCurbJD. Beta(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program. Stroke2001; 32: 1701–1706.
20.
van GoorMPAlblasCLLeebeekFWKoudstaalPJDippelDW. Do antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TIA or ischemic stroke?Acta Neurol Scand2004; 109: 410–415.
21.
GinsburgKSLiangMHNewcomerL. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med1992; 117: 997–1002.
22.
LarochePBerardMRouquetteAMDesgruelleCBoffaMC. Advantage of using both anionic and zwitterionic phospholipid antigens for the detection of antiphospholipid antibodies. Am J Clin Pathol1996; 106: 549–554.
23.
BranchDWSilverRPierangeliSvan LeeuwenIHarrisEN. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol1997; 89: 549–555.
24.
BertolacciniMLRochBAmengualOAtsumiTKhamashtaMAHughesGRV. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome. Br J Rheumatol1998; 37: 1229–1232.
25.
FialovaLMikulikovaLMatous-MalbohanIBenesovaOZwingerA. Prevalence of various antiphospholipid antibodies in pregnant women. Physiol Res2000; 49: 299–305.
26.
FranklinRDKuttehWH. Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population. Hum Reprod2002; 17: 2981–2985.
27.
AmorosoAMitterhoferAPDel PortoF. Antibodies to anionic phospholipids and anti-beta2-GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus. Hum Immunol2003; 64: 265–273.
28.
GharaviAEHarrisENAshersonRAHughesGR. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis1987; 46: 1–6.
29.
TeboAEJaskowskiTDPhansalkarARLitwinCMBranchDWHillHR. Diagnostic performance of phospholipid-specific assays for the evaluation of antiphospholipid syndrome. Am J Clin Pathol2008; 129: 870–875.
30.
TeboAEJaskowskiTDHillHRBranchDW. Clinical relevance of multiple antibody specificity testing in anti-phospholipid syndrome and recurrent pregnancy loss. Clin Exp Immunol2008; 154: 332–338.
31.
CampbellALPierangeliSSWellhausenSHarrisEN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost1995; 73: 529–534.
32.
GharaviAEPierangeliSS. Origin of antiphospholipid antibodies: Induction of aPL by viral peptides. Lupus1998; Suppl. 2: S52–S54.
33.
MatznerWChongPXuGChingW. Characterization of antiphospholipid antibodies in women with recurrent spontaneous abortions. J Reprod Med1994; 39: 27–30.
YetmanDLKuttehWH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil Steril1996; 66: 540–546.
36.
KuttehWHCoreyAJaslowCR. Antiphospholipid antibodies and recurrent pregnancy loss: Prevalence of anticardiolipin antibodies, the lupus anticoagulant, and antiphosphatidyl serine antibodies. Lupus2010; 19: C156 (abstract).
37.
PeacemanAMSilverRKMacGregorSNSocolML. Interlaboratory variation in antiphospholipid antibody testing. Am J Obstet Gynecol1992; 166: 1780–1784; discussion 4–7.
38.
CarrerasLOForastieroRRMartinuzzoME. Which are the best biological markers of the antiphospholipid syndrome?J Autoimmun2000; 15: 163–172.
39.
KuttehWHFranklinRD. Assessing the variation in antiphospholipid antibody (APA) assays: comparison of results from 10 centers. Am J Obstet Gynecol2004; 191: 440–448.
40.
KatsuragawaHKanzakiHInoueTHiranoTMoriTRoteNS. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion. Biol Reprod1997; 56: 50–58.
41.
FranklinRDKuttehWH. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet Gynecol2003; 101: 455–462.
GrecoTPAmosMDConti-KellyAMNaranjoJDIjdoJW. Testing for the antiphospholipid syndrome: importance of IgA anti-beta 2-glycoprotein I. Lupus2000; 9: 33–41.
44.
WilsonWAFaghiriZTaheriFGharaviAE. Significance of IgA antiphospholipid antibodies. Lupus1998; 7: S110–S113.
45.
WeidmannCEWallaceDJPeterJBKnightPJBearMBKlinenbergJR. Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J Rheumatol1988; 15: 74–79.
46.
TajimaCSuzukiYMizushimaYIchikawaY. Clinical significance of immunoglobulin A antiphospholipid antibodies: possible association with skin manifestations and small vessel vasculitis. J Rheumatol1998; 25: 1730–1736.
47.
LopezLRSantosMEEspinozaLRLa RosaFG. Clinical significance of immunoglobulin A versus immunoglobulins G and M anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Correlation with thrombosis, thrombocytopenia, and recurrent abortion. Am J Clin Pathol1992; 98: 449–454.
48.
MolinaJFGutierrez-UrenaSMolinaJ. Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol1997; 24: 291–296.
49.
WongKLLiuHWHoKChanKWongR. Anticardiolipin antibodies and lupus anticoagulant in Chinese patients with systemic lupus erythematosus. J Rheumatol1991; 18: 1187–1192.
50.
CucurullEGharaviAEDiriEMendezEKapoorDEspinozaLR. IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci1999; 318: 55–60.
51.
KalunianKCPeterJBMiddlekauffHR. Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med1988; 85: 602–608.
52.
Selva-O'CallaghanAOrdi-RosJMonegal-FerranFMartinezNCortes-HernandezFVilardell-TarresM. IgA anticardiolipin antibodies – relation with other antiphospholipid antibodies and clinical significance. Thromb Haemost1998; 79: 282–285.
53.
Alarcon-SegoviaDDelezéMOriaCV. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine (Baltimore)1989; 68: 353–365.
54.
SpadaroARiccieriVTerracinaSRinaldiTTaccariEZoppiniA. Class specific rheumatoid factors and antiphospholipid syndrome in systemic lupus erythematosus. Lupus2000; 9: 56–60.
55.
PierangeliSSLiuXWBarkerJHAndersonGHarrisEN. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost1995; 74: 1361–1367.
56.
LakosGKissERegeczyN. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol1999; 117: 574–579.
57.
LeeRMBrownMABranchDWWardKSilverRM. Anticardiolipin and anti-beta2-glycoprotein-I antibodies in preeclampsia. Obstet Gynecol2003; 102: 294–300.
58.
DiriECucurullEGharaviAE. Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype. Lupus1999; 8: 263–268.
59.
BertolacciniMLAtsumiTEscudero-ContrerasAKhamashtaMAHughesGRV. The value of IgA antiphospholipid testing for the diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol2001; 28: 2637–2643.
60.
DanowskiAKicklerTSPetriM. Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol2006; 33: 1775–1779.
61.
PetriM. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. Lupus2010; 19: 419–423.
62.
StaubHLNormanGLCrowtherT. Antibodies to the atherosclerotic plaque components beta2-glycoprotein I and heat-shock proteins as risk factors for acute cerebral ischemia. Arq Neuropsiquiatr2003; 61: 757–763.
63.
StaubHLFranckMRanzolinANormanGLIversonGMvon MuhlenCA. IgA antibodies to beta2-glycoprotein I and atherosclerosis. Autoimmun Rev2006; 6: 104–106.
64.
RanzolinABohnJMNormanGL. Anti-beta2-glycoprotein I antibodies as risk factors for acute myocardial infarction. Arq Bras Cardiol2004; 83: 37–40; 141–144.
65.
StaubHLvon MuhlenCANormanGL. Beta2-glycoprotein I IgA antibodies and ischaemic stroke. Rheumatology (Oxford)2006; 45: 645–646. (author reply 6).
66.
FranckMStaubHLPetraccoJB. Autoantibodies to the atheroma component beta2-glycoprotein I and risk of symptomatic peripheral artery disease. Angiology2007; 58: 295–302.
67.
YamadaHTsutsumiAIchikawaKKatoEHKoikeTFujimotoS. IgA-class anti-beta2-glycoprotein I in women with unexplained recurrent spontaneous abortion. Arthritis Rheum1999; 42: 2727–2728.
68.
LeeRMBranchDWSilverRM. Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol2001; 185: 748–753.
69.
AkhterEBinderWShumsZMagderLPetriM. Novel antiphospholipid antibodies and stroke in SLE. Lupus2010; 19: C124 (abstract).
70.
Martinez-MartinezLAAguilar-ValenzuelaRSeifABinderWAlarconGSPierangeliS. Do clinically relevant IgA anti-b2glycoprotein I (anti-b2GPI) antibodies bind to DIV/V of b2GPI?Lupus2010; 19: C130 (abstract).
71.
IversonGMvon MuhlenCAStaubHLLassenAJBinderWNormanGL. Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI. J Autoimmun2006; 27: 266–271.
72.
KumarSPapalardoESunkureddiPNajamSGonzalezEBPierangeliSS. Isolated elevation of IgA anti-beta2glycoprotein I antibodies with manifestations of antiphospholipid syndrome: a case series of five patients. Lupus2009; 18: 1011–1014.
73.
Sweiss NJ, Bo R, Kapadia R, et al. IgA anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus. PLoS One 2010; 5.
74.
GabetaSNormanGLGatselisN. IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. J Clin Immunol2008; 28: 501–511.
75.
BoinFFranchiniSColantuoniERosenAWigleyFMCasciola-RosenL. Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients. Arthritis Rheum2009; 60: 2480–2489.
76.
SeifAAlarcónGSAguilar-ValenzuelaR. Are IgA anti-b2glycoprotein I clinically relevant?Lupus2010; 19: C133 (abstract).
77.
Mehrani T and Petri M. Association of IgA Anti-b2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus. J Rheumatol 2010[Epub ahead of print].
78.
ArvieuxJDarnigeLCaronCReberGBensaJCColombMG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost1995; 74: 1120–1125.
79.
PengoVBiasoloABroccoTTonettoSRuffattiA. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid reactive antibodies. Thromb Haemost1996; 75: 721–724.
80.
BertolacciniMLAtsumiTKhamashtaMAAmengualOHughesGR. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol1998; 25: 1104–1108.
81.
VaaralaOPuurunenMManttariMManninenVAhoKPalosuoT. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost1996; 75: 456–459.
82.
HorbachDAvan OortEDondersRCDerksenRHde GrootPG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost1996; 76: 916–924.
83.
GalliMBerettaGDaldossiMBeversEMBarbuiT. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost1997; 77: 486–491.
84.
ForastieroRRMartinuzzoMECerratoGSKordichLCCarrerasLO. Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost1997; 78: 1008–1014.
85.
DonohoeSMackieIJIsenbergDMachinSJ. Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. Br J Haematol2001; 113: 544–549.
86.
TincaniAMorozziGAfeltraA. Antiprothrombin antibodies: a comparative analysis of homemade and commercial methods. A collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA). Clin Exp Rheumatol2007; 25: 268–274.
87.
RauchJTannenbaumMNevilleCFortinPR. Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin. Thromb Haemost1998; 80: 936–941.
88.
BertolacciniMLAtsumiTKoikeTHughesGRKhamashtaMA. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost2005; 93: 289–297.
89.
GalliMLucianiDBertoliniGBarbuiT. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood2003; 102: 2717–2723.
90.
ZanonESaggioratoGRamonRGirolamiAPagnanAPrandoniP. Anti-prothrombin antibodies as a potential risk factor of recurrent venous thromboembolism. Thromb Haemost2004; 91: 255–258.
91.
PalosuoTVirtamoJHaukkaJ. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men – a nested case-control study. Thromb Haemost1997; 78: 1178–1182.
92.
TsutsumiAHayashiTChinoY. Significance of antiprothrombin antibodies in patients with systemic lupus erythematosus: clinical evaluation of the antiprothrombin assay and the antiphosphatidylserine/prothrombin assay, and comparison with other antiphospholipid antibody assays. Mod Rheumatol2006; 16: 158–164.
93.
AtsumiTIekoMBertolacciniML. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum2000; 43: 1982–1993.
94.
ForastieroRMartinuzzoMPomboG. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost2005; 3: 1231–1238.
95.
BizzaroNGhirardelloAZampieriS. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost2007; 5: 1158–1164.
96.
ForastieroRMartinuzzoMIglesias VarelaMLCerratoG. Multiple (triple or quadruple) aPL positivity is much more prevalent in patients with definite antiphospholipid syndrome. Lupus2010; 19: C109 (abstract).
97.
FunkeABertolacciniMLAtsumiTAmengualOKhamashtaMAHughesGRV. Autoantibodies to prothrombin-phosphatidylserine complex: clinical significance in systemic lupus erythematosus. Arthritis Rheum1998; 41: S240 (abstract).
98.
AtsumiTKoikeT. Antiprothrombin antibody: why do we need more assays?Lupus2010; 19: 436–439.
99.
BinderWLewisSShumsZ. Clinical significance of IgG and IgM autoantibodies that target the complex of phosphatidylserine and prothrombin. Lupus2010; 19: C134 (abstract).
100.
GerkeVMossSE. Annexins: from structure to function. Physiol Rev2002; 82: 331–371.
101.
MortimerJCLaohavisitAMacphersonN. Annexins: multifunctional components of growth and adaptation. J Exp Bot2008; 59: 533–544.
102.
TaitJFSakataMMcMullenBA. Placental anticoagulant proteins: isolation and comparative characterization of four members of the lipocortin family. Biochemistry1988; 27: 6268–6276.
103.
RandJHWuXXAndreeHA. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulant" phenomenon. Blood1998; 92: 1652–1660.
104.
RandJHWuXXQuinnAS. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol2003; 163: 1193–1200.
105.
HanlyJGSmithSA. Anti-beta2-glycoprotein I (GPI) autoantibodies, annexin V binding and the anti-phospholipid syndrome. Clin Exp Immunol2000; 120: 537–543.
106.
GaspersicNAmbrozicABozicBMajhencJSvetinaSRozmanB. Annexin A5 binding to giant phospholipid vesicles is differentially affected by anti-beta2-glycoprotein I and anti-annexin A5 antibodies. Rheumatology (Oxford)2007; 46: 81–86.
107.
TomerABar-LevSFleisherSShenkmanBFrigerMAbu-ShakraM. Antiphospholipid antibody syndrome: the flow cytometric annexin A5 competition assay as a diagnostic tool. Br J Haematol2007; 139: 113–120.
108.
RandJHWuXXLapinskiR. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood2004; 104: 2783–2790.
109.
de LaatBWuXXvan LummelMDerksenRHde GrootPGRandJH. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood2007; 109: 1490–1494.
110.
RandJHArslanAAWuXX. Reduction of circulating annexin A5 levels and resistance to annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. Am J Obstet Gynecol2006; 194: 182–188.
